ESMO 2019
ESMO 2019 Prostate Cancer
- ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
- ESMO 2019: Invited Discussant - Phase 3 PROfound Study for Metastatic Castration-resistant Prostate Cancer (LBA12)
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Is there a Role for Radical Surgery?
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Advances in Pelvic Nodal Radiotherapy
ESMO 2019 Kidney Cancer
- ESMO 2019: Invited Discussant: (911PD and 912PD) New Anti-Angiogenic Treatments for Kidney Cancer
- ESMO 2019: Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: A Subgroup Analysis on Efficacy and Biomarkers from the Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab plus Axitinib versus Sunitinib
- ESMO 2019: Results from a Global Patient Survey: Diagnosis, Management, and Burden of Renal Cell Carcinomas - A Medical Oncologist’s Perspective
- ESMO 2019: ADAPTeR: Anti-PD1 Therapy as Operative Therapy in Metastatic Renal Cell Carcinoma
- ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma
ESMO 2019 Bladder Cancer
- ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma
- ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma
- ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?
- ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma
- ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019 Testicular Cancer
- ESMO 2019: Invited Discussant: Testicular and Kidney Cancer (913PD - APACHE (Testicular), 914PD (Testicular) , and 915PD (RCC))
- ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated HCG – a Study of the G3
- ESMO 2019: APACHE: An Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort
- ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated Human Chorionic Gonadotrophin – Study of the G3
- ESMO 2019: APACHE: An Open Label, Randomized, Phase II Study of Durvalumab Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort
E-Newsletters
Free Daily and Weekly newsletters offered by content of interest
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.